Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3425389 Target Snapshot

Serine/threonine-protein phosphatase 5 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
63Compounds
46Assays
1Approved Drugs
42.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Serine/threonine-protein phosphatase 5 shows clinical signal disease relevance led by glioblastoma multiforme. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P53041. Start with glioblastoma multiforme, then reuse UniProt P53041 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with glioblastoma multiforme, then reuse UniProt P53041 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
glioblastoma multiforme

Serine/threonine-protein phosphatase 5 shows clinical signal disease relevance led by glioblastoma multiforme. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with glioblastoma multiforme because it currently carries clinical signal support. Linked drugs include LB-100. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein phosphatase 5 as ChEMBL target CHEMBL3425389, mapped to UniProt P53041. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein phosphatase 5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3425389
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P53041
Serine/threonine-protein phosphatase 5
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein phosphatase 5 is the right protein anchor across sources, using UniProt P53041 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why glioblastoma multiforme is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSerine/threonine-protein phosphatase 5
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP53041
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein phosphatase 5
UniProt AccessionP53041
Component TypeProtein
Sequence Length499 aa

Serine/threonine-protein phosphatase 5

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Serine/threonine-protein phosphatase 5, mapped to UniProt P53041. Sequence length is 499 aa.

Mapped IDP53041
Review nameSerine/threonine-protein phosphatase 5
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Serine/threonine-protein phosphatase 5 shows clinical signal disease relevance led by glioblastoma multiforme. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugLB-100
Clinical signal Phase II
oligodendroglioma
1 linked drug · 1 direct · 1 efficacy
Linked drugLB-100
Clinical signal Phase II
Paraganglioma
1 linked drug · 1 direct · 1 efficacy
Linked drugLB-100
Clinical signal Phase I
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugLB-100
Clinical signal Phase I
clear cell adenocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugLB-100
Clinical signal Phase I
colorectal carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugLB-100
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with glioblastoma multiforme because it currently carries clinical signal support. Linked drugs include LB-100. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseglioblastoma multiforme
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC5030.0
EC506.0
KD6.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5593159 9.27 Kd 0.54 Preclinical
CHEMBL444092 9.0 IC50 1.0 Preclinical
CHEMBL430266 8.52 IC50 3.0 Preclinical
CHEMBL5268133 8.46 IC50 3.5 Preclinical
CHEMBL5276260 8.4 IC50 4.0 Preclinical
CHEMBL505512 8.0 IC50 10.0 Preclinical
CHEMBL5276593 7.92 IC50 11.9 Preclinical
CHEMBL5561795 7.52 IC50 30.0 Preclinical
CHEMBL48449 6.4 IC50 400.0 Approved
CHEMBL5405890 6.16 IC50 700.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
4
5.5
7
6.0
0
6.5
0
7.0
2
7.5
3
8.0
1
8.5
3
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CANTHARIDIN
CHEMBL48449
Approved 2023
Properties Compare Identifier
Assay Landscape

Assay Landscape

46
Total Assays
20
Tested Compounds
1
Assay Types
Binding — 46 assays, 20 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 38 16 6.4
assay format 4 4 6.1
cell-based format 4 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine